Akorn Inc (AKRX) 41.24 $AKRX
Actavis Likely to Continue Selling Namenda IR Tablets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 2:20PM CST
Actavis plc (ACT) may face an injunction under which the company will have to continue selling Namenda IR.
IPXL: 31.16 (-0.74), ACT: 259.00 (-4.00), AKRX: 41.24 (+0.38), MYL: 53.32 (-1.39)
Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines
PR Newswire - Fri Dec 12, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), Akorn Inc. (NASDAQ: AKRX), and The Medicines Company (NASDAQ: MDCO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, December 11, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,596.34, up 0.36% and the NASDAQ Composite closed at 4,708.16, up 0.52%. The S&P 500 finished the session 0.45% higher at 2,035.33. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
MDCO: 25.39 (-0.19), AKRX: 41.24 (+0.38), MRK: 57.72 (-1.62), PFE: 30.95 (-0.70), ABBV: 65.27 (-1.76)
Supernus Faces another Patent Challenge for Oxtellar XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 2:20PM CST
Supernus Pharmaceuticals, Inc. (SUPN) received a Para IV notice from TWi Pharma, seeking approval for its generic version of Supernus' Oxtellar XR in the U.S.
ACT: 259.00 (-4.00), AKRX: 41.24 (+0.38), SUPN: 8.72 (+0.02), MYL: 53.32 (-1.39)
Supernus Faces New Patent Challenge for Trokendi XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:50PM CST
Supernus Pharmaceuticals, Inc. (SUPN) received a Paragraph IV notice from Par, which is looking to get its generic version of Supernus' Trokendi XR approved in the U.S.
ACT: 259.00 (-4.00), AKRX: 41.24 (+0.38), SUPN: 8.72 (+0.02), MYL: 53.32 (-1.39)
Energy Sector Drags On Stocks; Lakeland, Spirit, Akorn Rise
at Investor's Business Daily - Wed Dec 10, 9:28AM CST
Stocks opened in the hole Wednesday, posting quiet losses as energy stocks suffered many of the largest early declines. The Dow Jones industrial average and the S&P 500 each slipped 0.6%. The Nasdaq shed 0.4%. Volume was sharply lower, as the stock...
SAVE: 68.12 (-0.88), AKRX: 41.24 (+0.38), COST: 137.88 (-3.53), LAKE: 10.79 (-0.40), XOM: 86.60 (-2.60), VRA: 20.68 (-1.01), FRAN: 15.55 (+0.57), KKD: 19.05 (+0.64), CVX: 102.38 (-2.53), TOL: 31.56 (-0.57), HOV: 4.31 (+0.02)
Akorn Rises 3.50% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Dec 09, 5:10PM CST
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $39.01 to a high of $41.31. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $40.50 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AKRX: 41.24 (+0.38)
Stocks Snap Back After Morning Downdraft; AutoZone Jumps
at Investor's Business Daily - Tue Dec 09, 3:16PM CST
Major averages recovered early losses Tuesday, an impressive performance considering the carnage in overseas markets overnight. At the close, the Nasdaq turned a 1.4% intraday loss into a 0.5% gain. The S&P 500 also fell more than 1% in the morning...
T: 32.16 (-0.55), BIDU: 229.32 (+0.09), SAVE: 68.12 (-0.88), AAP: 160.25 (+1.09), AZO: 604.73 (+2.34), AKRX: 41.24 (+0.38), ORLY: 191.99 (+0.12), DATA: 80.59 (-2.63), VZ: 45.58 (-0.78), BABA: 105.11 (+0.14)
Stocks Recover After Sharp Losses; Nasdaq Turns Positive
at Investor's Business Daily - Tue Dec 09, 2:01PM CST
Major averages recovered well above session lows Tuesday, an impressive performance amid a sell-off in China and European markets. The Dow Jones industrial average lost 0.5%, weighed down by Verizon (VZ) and AT&T (T). The S&P 500 eased 0.3% after...
CAVM: 59.07 (+0.30), T: 32.16 (-0.55), SAVE: 68.12 (-0.88), AZO: 604.73 (+2.34), AKRX: 41.24 (+0.38), HQY: 22.32 (-1.51), VZ: 45.58 (-0.78)
Stocks Swoon In Heavy Trade; Spirit Airlines Spirals Lower
at Investor's Business Daily - Tue Dec 09, 9:38AM CST
Stocks opened to broad and breathtaking losses Tuesday, as harsh selling overseas and weakened energy prices took a bite out of investor confidence. The Nasdaq tumbled 1.1% at the starting bell. The S&P 500 and the Dow Jones industrial average fell...
AMBA: 46.33 (-1.64), TSLA: 207.00 (-1.88), MNST: 105.11 (-3.28), GPRO: 60.52 (+0.47), CAVM: 59.07 (+0.30), AKRX: 41.24 (+0.38), KFY: 26.57 (-1.28), SAVE: 68.12 (-0.88), HQY: 22.32 (-1.51), MRK: 57.72 (-1.62), KKD: 19.05 (+0.64), VZ: 45.58 (-0.78)
Actavis' Antibiotic Backed for FDA Approval, Response in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 5:30PM CST
Actavis' (ACT) ceftazidime-avibactam got favorable recommendation from the Anti-Infective Drugs Advisory Committee for the treatment of complicated intra-abdominal infections and complicated urinary tract infections.
ACT: 259.00 (-4.00), CBST: 96.31 (+0.04), AKRX: 41.24 (+0.38), AZN: 71.80 (-1.80)
Stocks Sink In Late Trading: Tesla, McDonald's Dive
at Investor's Business Daily - Mon Dec 08, 2:06PM CST
Stocks stretched losses heading into the final hour of trading Monday. In the stock market today the Nasdaq fell 0.9%, the S&P 500 dropped 0.7%, and the Dow trimmed 0.6%. Volume was tracking higher across the board compared with Friday's levels. From...
TSLA: 207.00 (-1.88), AKRX: 41.24 (+0.38), UTX: 112.15 (-1.89), JAZZ: 165.12 (-8.09), MCD: 90.62 (-0.35), CELG: 114.49 (-2.25)
Stock Market Today: Jazz Hits New High, In Buy Range
at Investor's Business Daily - Mon Dec 08, 11:02AM CST
Stocks were lower at midday Monday following mixed overseas economic data. The Nasdaq was up 0.1%, while the S&P 500 and the Dow Jones industrial average were each off a fraction. Volume was tracking lower on both major exchanges in the stock market...
ANET: 67.95 (+0.05), GILD: 104.13 (-0.18), AKRX: 41.24 (+0.38), JAZZ: 165.12 (-8.09), TASR: 23.19 (unch), CSCO: 26.85 (-0.14), CELG: 114.49 (-2.25)
Akorn (AKRX) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 8:10AM CST
Akorn (AKRX) Sees Hammer Chart Pattern: Time to Buy?
AKRX: 41.24 (+0.38)
Actavis Launches Generic of Shire's ADHD Drug Intuniv - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 5:45PM CST
Actavis (ACT) launched its generic version of Shire's attention deficit hyperactivity disorder drug Intuniv in the U.S.
AGN: 208.47 (-2.67), ACT: 259.00 (-4.00), AKRX: 41.24 (+0.38), SHPG: 213.70 (-0.41)
Teva First to Launch a Generic of Novartis' Exforge HCT - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 3:30PM CST
Teva (TEVA), which has launched its generic version of Novartis' Exforge HCT in the U.S., will enjoy 180 days exclusivity.
AKRX: 41.24 (+0.38), MYL: 53.32 (-1.39), TEVA: 55.92 (-0.92), NVS: 93.52 (-0.82)
Stocks Mixed And Quiet At Open; Chip Stocks Move Higher
at Investor's Business Daily - Wed Nov 26, 9:34AM CST
Stocks opened narrowly mixed Wednesday as investors geared up for the market's one-day Thanksgiving holiday. The Nasdaq groped out a 0.2% gain. The S&P 500 added 0.1%, and the Dow Jones industrial average hung a fraction into the red. Trade was...
VNET: 15.72 (-0.78), AKRX: 41.24 (+0.38), ADI: 55.92 (-0.33), SDRL: 11.06 (-0.15), CTRP: 45.34 (+2.32), AVGO: 99.20 (-1.35)
Post Earnings Update: Akorn Has Sunk 4.1% Lower in Past 2 Weeks (AKRX)
Comtex SmarTrend(R) - Mon Nov 24, 9:50AM CST
18 days ago, on November 6th, 2014, Akorn (NASDAQ:AKRX) reported its earnings. Analysts, on average, expected earnings of $0.25 per share on sales of $155.3 million. Akorn actually reported earnings of $0.27 per share on sales of $132.7 million, beating EPS estimates by $0.02 and missing revenue estimates by $22.5 million. Since the company's report, shares of Akorn have fallen from $37.88 to $36.32, representing a loss of 4.1% in the past 18 days.
AKRX: 41.24 (+0.38)
Akorn (AKRX): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 7:42AM CST
Akorn is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
AKRX: 41.24 (+0.38)
Supernus Pharmaceuticals (SUPN) in Focus: Stock Up 9.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:32AM CST
Supernus Pharmaceuticals, Inc. (SUPN) was a big mover last session, as the company saw its shares nearly 10% on the day.
EVOK: 5.49 (-0.29), AKRX: 41.24 (+0.38), SUPN: 8.72 (+0.02)
Corium International (CORI) Jumps: Stock Moves 14.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:25AM CST
Corium International (CORI) was a big mover last session, with shares rising over 14% on the day.
IPXL: 31.16 (-0.74), CORI: 5.86 (-0.06), AKRX: 41.24 (+0.38), MYL: 53.32 (-1.39)
Actavis Likely to Continue Selling Namenda IR Tablets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 2:20PM CST
Actavis plc (ACT) may face an injunction under which the company will have to continue selling Namenda IR.
IPXL: 31.16 (-0.74), ACT: 259.00 (-4.00), AKRX: 41.24 (+0.38), MYL: 53.32 (-1.39)
Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines
PR Newswire - Fri Dec 12, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), Akorn Inc. (NASDAQ: AKRX), and The Medicines Company (NASDAQ: MDCO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, December 11, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,596.34, up 0.36% and the NASDAQ Composite closed at 4,708.16, up 0.52%. The S&P 500 finished the session 0.45% higher at 2,035.33. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
MDCO: 25.39 (-0.19), AKRX: 41.24 (+0.38), MRK: 57.72 (-1.62), PFE: 30.95 (-0.70), ABBV: 65.27 (-1.76)
Supernus Faces another Patent Challenge for Oxtellar XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 2:20PM CST
Supernus Pharmaceuticals, Inc. (SUPN) received a Para IV notice from TWi Pharma, seeking approval for its generic version of Supernus' Oxtellar XR in the U.S.
ACT: 259.00 (-4.00), AKRX: 41.24 (+0.38), SUPN: 8.72 (+0.02), MYL: 53.32 (-1.39)
Supernus Faces New Patent Challenge for Trokendi XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:50PM CST
Supernus Pharmaceuticals, Inc. (SUPN) received a Paragraph IV notice from Par, which is looking to get its generic version of Supernus' Trokendi XR approved in the U.S.
ACT: 259.00 (-4.00), AKRX: 41.24 (+0.38), SUPN: 8.72 (+0.02), MYL: 53.32 (-1.39)
Energy Sector Drags On Stocks; Lakeland, Spirit, Akorn Rise
at Investor's Business Daily - Wed Dec 10, 9:28AM CST
Stocks opened in the hole Wednesday, posting quiet losses as energy stocks suffered many of the largest early declines. The Dow Jones industrial average and the S&P 500 each slipped 0.6%. The Nasdaq shed 0.4%. Volume was sharply lower, as the stock...
SAVE: 68.12 (-0.88), AKRX: 41.24 (+0.38), COST: 137.88 (-3.53), LAKE: 10.79 (-0.40), XOM: 86.60 (-2.60), VRA: 20.68 (-1.01), FRAN: 15.55 (+0.57), KKD: 19.05 (+0.64), CVX: 102.38 (-2.53), TOL: 31.56 (-0.57), HOV: 4.31 (+0.02)
Akorn Rises 3.50% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Dec 09, 5:10PM CST
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $39.01 to a high of $41.31. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $40.50 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AKRX: 41.24 (+0.38)
Stocks Snap Back After Morning Downdraft; AutoZone Jumps
at Investor's Business Daily - Tue Dec 09, 3:16PM CST
Major averages recovered early losses Tuesday, an impressive performance considering the carnage in overseas markets overnight. At the close, the Nasdaq turned a 1.4% intraday loss into a 0.5% gain. The S&P 500 also fell more than 1% in the morning...
T: 32.16 (-0.55), BIDU: 229.32 (+0.09), SAVE: 68.12 (-0.88), AAP: 160.25 (+1.09), AZO: 604.73 (+2.34), AKRX: 41.24 (+0.38), ORLY: 191.99 (+0.12), DATA: 80.59 (-2.63), VZ: 45.58 (-0.78), BABA: 105.11 (+0.14)
Stocks Recover After Sharp Losses; Nasdaq Turns Positive
at Investor's Business Daily - Tue Dec 09, 2:01PM CST
Major averages recovered well above session lows Tuesday, an impressive performance amid a sell-off in China and European markets. The Dow Jones industrial average lost 0.5%, weighed down by Verizon (VZ) and AT&T (T). The S&P 500 eased 0.3% after...
CAVM: 59.07 (+0.30), T: 32.16 (-0.55), SAVE: 68.12 (-0.88), AZO: 604.73 (+2.34), AKRX: 41.24 (+0.38), HQY: 22.32 (-1.51), VZ: 45.58 (-0.78)
Stocks Swoon In Heavy Trade; Spirit Airlines Spirals Lower
at Investor's Business Daily - Tue Dec 09, 9:38AM CST
Stocks opened to broad and breathtaking losses Tuesday, as harsh selling overseas and weakened energy prices took a bite out of investor confidence. The Nasdaq tumbled 1.1% at the starting bell. The S&P 500 and the Dow Jones industrial average fell...
AMBA: 46.33 (-1.64), TSLA: 207.00 (-1.88), MNST: 105.11 (-3.28), GPRO: 60.52 (+0.47), CAVM: 59.07 (+0.30), AKRX: 41.24 (+0.38), KFY: 26.57 (-1.28), SAVE: 68.12 (-0.88), HQY: 22.32 (-1.51), MRK: 57.72 (-1.62), KKD: 19.05 (+0.64), VZ: 45.58 (-0.78)
Actavis' Antibiotic Backed for FDA Approval, Response in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 5:30PM CST
Actavis' (ACT) ceftazidime-avibactam got favorable recommendation from the Anti-Infective Drugs Advisory Committee for the treatment of complicated intra-abdominal infections and complicated urinary tract infections.
ACT: 259.00 (-4.00), CBST: 96.31 (+0.04), AKRX: 41.24 (+0.38), AZN: 71.80 (-1.80)
Stocks Sink In Late Trading: Tesla, McDonald's Dive
at Investor's Business Daily - Mon Dec 08, 2:06PM CST
Stocks stretched losses heading into the final hour of trading Monday. In the stock market today the Nasdaq fell 0.9%, the S&P 500 dropped 0.7%, and the Dow trimmed 0.6%. Volume was tracking higher across the board compared with Friday's levels. From...
TSLA: 207.00 (-1.88), AKRX: 41.24 (+0.38), UTX: 112.15 (-1.89), JAZZ: 165.12 (-8.09), MCD: 90.62 (-0.35), CELG: 114.49 (-2.25)
Stock Market Today: Jazz Hits New High, In Buy Range
at Investor's Business Daily - Mon Dec 08, 11:02AM CST
Stocks were lower at midday Monday following mixed overseas economic data. The Nasdaq was up 0.1%, while the S&P 500 and the Dow Jones industrial average were each off a fraction. Volume was tracking lower on both major exchanges in the stock market...
ANET: 67.95 (+0.05), GILD: 104.13 (-0.18), AKRX: 41.24 (+0.38), JAZZ: 165.12 (-8.09), TASR: 23.19 (unch), CSCO: 26.85 (-0.14), CELG: 114.49 (-2.25)
Akorn (AKRX) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 8:10AM CST
Akorn (AKRX) Sees Hammer Chart Pattern: Time to Buy?
AKRX: 41.24 (+0.38)
Actavis Launches Generic of Shire's ADHD Drug Intuniv - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 5:45PM CST
Actavis (ACT) launched its generic version of Shire's attention deficit hyperactivity disorder drug Intuniv in the U.S.
AGN: 208.47 (-2.67), ACT: 259.00 (-4.00), AKRX: 41.24 (+0.38), SHPG: 213.70 (-0.41)
Teva First to Launch a Generic of Novartis' Exforge HCT - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 3:30PM CST
Teva (TEVA), which has launched its generic version of Novartis' Exforge HCT in the U.S., will enjoy 180 days exclusivity.
AKRX: 41.24 (+0.38), MYL: 53.32 (-1.39), TEVA: 55.92 (-0.92), NVS: 93.52 (-0.82)
Stocks Mixed And Quiet At Open; Chip Stocks Move Higher
at Investor's Business Daily - Wed Nov 26, 9:34AM CST
Stocks opened narrowly mixed Wednesday as investors geared up for the market's one-day Thanksgiving holiday. The Nasdaq groped out a 0.2% gain. The S&P 500 added 0.1%, and the Dow Jones industrial average hung a fraction into the red. Trade was...
VNET: 15.72 (-0.78), AKRX: 41.24 (+0.38), ADI: 55.92 (-0.33), SDRL: 11.06 (-0.15), CTRP: 45.34 (+2.32), AVGO: 99.20 (-1.35)
Post Earnings Update: Akorn Has Sunk 4.1% Lower in Past 2 Weeks (AKRX)
Comtex SmarTrend(R) - Mon Nov 24, 9:50AM CST
18 days ago, on November 6th, 2014, Akorn (NASDAQ:AKRX) reported its earnings. Analysts, on average, expected earnings of $0.25 per share on sales of $155.3 million. Akorn actually reported earnings of $0.27 per share on sales of $132.7 million, beating EPS estimates by $0.02 and missing revenue estimates by $22.5 million. Since the company's report, shares of Akorn have fallen from $37.88 to $36.32, representing a loss of 4.1% in the past 18 days.
AKRX: 41.24 (+0.38)
Akorn (AKRX): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 7:42AM CST
Akorn is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
AKRX: 41.24 (+0.38)
Supernus Pharmaceuticals (SUPN) in Focus: Stock Up 9.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:32AM CST
Supernus Pharmaceuticals, Inc. (SUPN) was a big mover last session, as the company saw its shares nearly 10% on the day.
EVOK: 5.49 (-0.29), AKRX: 41.24 (+0.38), SUPN: 8.72 (+0.02)
Corium International (CORI) Jumps: Stock Moves 14.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:25AM CST
Corium International (CORI) was a big mover last session, with shares rising over 14% on the day.
IPXL: 31.16 (-0.74), CORI: 5.86 (-0.06), AKRX: 41.24 (+0.38), MYL: 53.32 (-1.39)
